EASI 100 as a Therapeutic Target in Pediatric Atopic Dermatitis
Open Access
- 1 January 2025
- journal article
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Abstract
Dupilumab, a monoclonal antibody targeting interleukin‐4 receptor alpha, has shown both robust efficacy and safety in pediatric atopic dermatitis (AD), but data on complete disease control (Eczema Area and Severity Index [EASI] 100) are scarce. A retrospective analysis of 25 pediatric patients at our institution with a median treatment duration of 20 months revealed a significant improvement in EASI scores, with 44.0% achieving EASI 100 at a median of 52 weeks of treatment. No significant differences were found between the group of patients achieving EASI 100 and those who did not. While this study provides additional insight into the efficacy and safety of dupilumab in pediatric AD, its limited sample size underscores the need for larger scale studies focusing on EASI 100 to better understand the factors influencing complete disease control and to optimize treatment strategies for pediatric patients with AD.Keywords
This publication has 14 references indexed in Scilit:
- A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 yearsJournal of Dermatological Treatment, 2023
- Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III TrialAmerican Journal of Clinical Dermatology, 2023
- Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2022
- Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center StudyThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Management of inadequate response and adverse effects to dupilumab in atopic dermatitisJournal of the American Academy of Dermatology, 2022
- Errors in Results SectionJAMA Dermatology, 2021
- Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemicClinical and Experimental Dermatology, 2021
- Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16‐week real‐life experience during the COVID ‐19 pandemic in ItalyDermatologic Therapy, 2021
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trialJournal of the American Academy of Dermatology, 2020
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020